Episode
Inaugural EP EdgeTM Journal Watch with Heart Rhythm Society: AVANT GUARD, LAA Closure, OCEAN, and the ALONE-AF Cognitive Substudy
- Podcast
- EP Edge Journal Watch
- Published
- Jun 1, 2026
- Duration seconds
- 1198
- Processing state
not_requested- Canonical source
- https://share.transistor.fm/s/0c400bf6
Actions
POST https://stenobird.com/v1/public/podcasts/ep-edge-journal-watch-7561379/episodes/inaugural-ep-edgetm-journal-watch-with-heart-rhythm-society-avant-guard-laa-closure-ocean-and-the-alone-af-cognitive-substudy/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/ep-edge-journal-watch-7561379/inaugural-ep-edgetm-journal-watch-with-heart-rhythm-society-avant-guard-laa-closure-ocean-and-the-alone-af-cognitive-substudy.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
The inaugural EP Edge Journal Watch and Heart Rhythm Society collaboration is here. In this first episode, Dr. Michael Lloyd from the Heart Rhythm Society Digital Education Committee joins Dr. Niraj Sharma , creator of EP Edge , to launch a new monthly format focused on the most clinically relevant literature in cardiac electrophysiology. This is not a routine article summary. It is a practical, physician-led discussion of the studies that matter in the EP lab, in clinic, and at the bedside. Electrophysiology literature is moving quickly. Important trials now appear across major journals, late-breaking sessions, society meetings, and digital platforms. Algorithms can identify highly cited papers. Search tools can rank articles. But clinical relevance still requires judgment. EP Edge Journal Watch was created to help close that gap. The goal is simple: identify the papers that deserve attention, place them in clinical context, and ask what they mean for real patients. In this inaugural episode, Dr. Lloyd and Dr. Sharma begin with AVANT GUARD , a major trial evaluating first-line pulsed field ablation in patients with persistent atrial fibrillation. The discussion goes beyond the headline. They examine patient selection, drug-naive persistent AF, procedural safety, the stroke signal, modified enrollment criteria, anticoagulation requirements, endpoint design, and the difference between symptom reduction and true AF burden reduction. The episode then turns to one of the most active areas in atrial fibrillation care: left atrial appendage closure . Dr. Lloyd and Dr. Sharma discuss CLOSURE AF and CHAMPION AF , two trials that asked similar questions but studied very different patient populations. The discussion focuses on stroke risk, bleeding risk, frailty, procedural comp…